BCL2 and Miyoshi myopathy: Recently, we investigated the Bcl-2 selective inhibitor, venetoclax (ABT-199), in relapsed/refractory MM and demonstrated its safety and efficacy both as a single agent [14] and in combination with other active anti-MM agents [15,16,17,18].